



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health/ NCI
9609 Medical Center Drive, Suite 530
Rockville, MD 20852
Office (240) 276-5530
Facsimile (240) 276-5504

July 11, 2019

Kathryn Ardizzone, Esq.
Knowledge Ecology International
1621 Connecticut Avenue, Suite 500
Washington, DC 20009
+1.202.332.2670
kathryn.ardizzone@keionline.org

Subject: Comments Submitted in Response to Federal Register Notice 2019-12707 (84 FR 28063), entitled
“Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies
for Cancer”

Dear Ms. Ardizzone:

Thank you for providing us with your comments regarding the above-referenced notice (“Notice”). As you indicated your comments were submitted on behalf of several organizations and individuals, we kindly request that you share our response with these same parties.

Prior to posting the Notice, the NCI determined that the criteria set forth in 37 CFR 404.7(a)(1)(ii)(A)-iii) were satisfied and that the prospective licensee is qualified, both technically and financially, to be granted an exclusive license to the Government’s intellectual property in the specified fields of use. The notice period provides an opportunity for public comment and possible objection to the proposed license.

We thank you for providing comments and will consider them, as appropriate, should a license be negotiated.

Sincerely,

Andrew Burke, Ph.D.
Senior Technology Transfer Manager